Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Drug Applications Face Rejection As China FDA Starts 'Intensive Review'

This article was originally published in SRA

Executive Summary

In a rare move, the China Food and Drug Administration has rejected 11 new drug applications (NDAs) from eight companies that were in its review queue, signaling more action to come as the agency increases punishments for clinical data forgery and prepares another intensive review campaign, its third in a decade.

Advertisement
Advertisement
UsernamePublicRestriction

Register